-
Clinical Ophthalmology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Update on thyroid eye disease and management
Review
(3478) Views (1350) Full article downloads
Authors: Erick D Bothun, Ryan A Scheurer, Andrew R Harrison, et al
Published Date October 2009
Volume 2009:3 Pages 543 - 551
DOI: http://dx.doi.org/10.2147/OPTH.S5228
Erick D Bothun,1,2 Ryan A Scheurer,1 Andrew R Harrison,1,3 Michael S Lee1,4,5
1Departments of Ophthalmology, 2Pediatrics, 3Otolaryngology, 4Neurosurgery, and 5Neurology, University of Minnesota, Minneapolis, Minnesota, USA
Abstract: Thyroid eye disease is a heterogeneous autoimmune orbital reaction typically manifesting in middle age. The inflammation may parallel or remain isolated from a related inflammatory cascade in the thyroid called Graves’ disease. The orbital manifestations can lead to severe proptosis, dry eyes, strabismus, and optic neuropathy. In this article, we will discuss this unique condition including the ophthalmic findings and management.
Keywords: Graves’ disease, thyroid eye disease, proptosis, orbital decompression, enlarged extraocular muscles
Other articles by Dr Andrew Harrison
Profile of Xeomin® (incobotulinumtoxinA) for the treatment of blepharospasm- Journal Indexing
See where all the Dove Press journals are indexed
- Interested in being a peer-reviewer?
Click here to register.
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- A computer-based anaglyphic system for the treatment of amblyopia
- Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%




